SELLAS Life Sciences Group, Inc. (SLS)
Automate Your Wheel Strategy on SLS
With Tiblio's Option Bot, you can configure your own wheel strategy including SLS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SLS
- Rev/Share 0.0
- Book/Share 0.3163
- PB 4.8687
- Debt/Equity 0.0313
- CurrentRatio 4.6418
- ROIC -1.3225
- MktCap 153657350.0
- FreeCF/Share -0.3841
- PFCF -4.5581
- PE -4.982
- Debt/Assets 0.0249
- DivYield 0
- ROE -1.9367
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock?
Published: June 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Galena Biopharma (SLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
New appointments of Drs. Philip C. Amrein and Alex Kentsis Validate Lead Galinpepimut-S and SLS009 Programs as Company Approaches Key Inflection Points This Year New appointments of Drs. Philip C. Amrein and Alex Kentsis Validate Lead Galinpepimut-S and SLS009 Programs as Company Approaches Key Inflection Points This Year
Read More
SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
- ASCO Presentation Supports SLS009 as a Potential Targeted Therapy for ASXL1 Mutated Colorectal Cancer – - 22,500 New Cases of Colorectal Cancer with High Microsatellite Instability per Year in the US: 55% ASXL1m Frequency – NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced preclinical efficacy of SLS009 (tambiciclib) in ASXL1 mutated colorectal cancer lines. The data are featured in a presentation, entitled “In vitro efficacy of CDK9 …
Read More
SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
New Data Suggest SLS009 (tambiciclib) May Overcome Resistance to Azacitidine-Venetoclax Regimen and Trigger Apoptosis of TP53 Mutated AML Cells New Data Suggest SLS009 (tambiciclib) May Overcome Resistance to Azacitidine-Venetoclax Regimen and Trigger Apoptosis of TP53 Mutated AML Cells
Read More
Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst
Published: March 31, 2025 by: Seeking Alpha
Sentiment: Neutral
Sellas Life Sciences Group, Inc.'s stock has dropped significantly, with a Hold rating due to uncertainty around the final Phase 3 trial data for GPS in AML. Interim results for GPS are promising but inconclusive; the trial continues until 80 patients die, creating investment uncertainty and ongoing cash burn. The company raised $25M in January 2025, extending its runway to late 2025, but may need more funds for regulatory and commercial plans.
Read More
SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
- Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in Difficult-to-Treat Non-GCB DLBCL (ABC DLBCL) Patients -
Read More
About SELLAS Life Sciences Group, Inc. (SLS)
- IPO Date 2008-03-12
- Website https://www.sellaslifesciences.com
- Industry Biotechnology
- CEO Dr. Angelos M. Stergiou M.D., ScD h.c.
- Employees 15